Ask the expert: How can hallucinations affect people with Parkinson’s?
Author: Saskia MairPublished: 14 January 2021
Prep: Cook: Serves:
Around 50% of people with Parkinson’s disease will experience hallucinations. But what are they – and what causes them? In the latest in our ‘Ask the expert’ series, Professor Per Odin shares what you need to know about the symptom
What are hallucinations?
Hallucinations are sensory experiences that appear real but are created by our brains. They can affect all five of our senses. You might hear voices that no one else hears, or see things that no one else sees. They are normally separate from illusions, which are distorted or misinterpreted real perceptions – for example, you could see a person where there is actually a tree.
What causes hallucinations in people with Parkinson’s disease?
Hallucinations are very common in Parkinson’s disease. More than half of patients experience them at some stage. They are normally thought to be an effect both of the condition itself and of Parkinson’s medication. The risk of hallucinations increases with cognitive impairment, longer disease duration, age and other diseases.
Visual (seeing) and auditory (hearing) hallucinations may occur as a side effect of antiparkinsonian drugs which are used to treat the condition. They are often dose-dependent – and in principle reversible.
What types of hallucinations can people with Parkinson’s experience?
Visual hallucinations are the most common in Parkinson’s disease. Auditory hallucinations occur mainly in depression. Tactile (touch) or olfactory (smell) sensations are unusual.
Often the symptom starts with lively dreams, then illusions, then hallucinations at night-time. After that hallucinations can also appear in the day. Initially the patient understands that the experience is a hallucination, but if things progress it becomes difficult to say what is real and not.
Further progression could mean that the hallucinations become scary, and patients can develop confusion or delusions (for example, believing that a partner is unfaithful). Auditive hallucinations are seldom linked to Parkinson’s.
Mild hallucinations do not need to impact life very much, and can even be experienced as entertaining in some cases. But when the hallucinations become more pronounced and it is difficult to differentiate them from reality, they can have a big effect.
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden.
Can hallucinations be treated?
The treatment for hallucinations consists primarily of removing any existing medical cause, especially reducing or stopping any triggering pharmacological cause – for example by reducing a dose or discontinuing treatment with a certain drug. If the increase in motor symptoms then becomes troublesome, a return to the earlier anti-Parkinson’s drug may be considered, but with the addition of an atypical neuroleptic drug.
Most neuroleptics (drugs against hallucinations and psychosis) can worsen Parkinson’s (sometimes dramatically) and are forbidden when treating people with the condition. Medications for dementia can also reduce the incidence of illusions and hallucinations when there is underlying cognitive impairment. Parkinson’s treatments are developing fast and it is likely that we will see even more effective ways of avoiding and treating hallucinations in the coming years.
The most important thing is to report hallucinations to your doctor or nurse, and to discuss if they should be treated in some way.
Do you have any advice for the family, friends and carers of people with Parkinson’s experiencing hallucinations?
Tell the patient that what they are experiencing is not real and do not pretend that you also experience the same thing. Be calm and friendly with the patient – experiencing hallucinations can be quite stressful.
Need to know
Per Odin is a neurologist, professor and head of the neurology department at Lund University, Sweden. He also works at an outpatient clinic in Bremen, Germany. He has focused on Parkinson’s disease, both clinically and in research, since 1987.
Helping people with Parkinson’s “take back control of their brain and body”
We talk to the founder of MyCognition
7 days ago
Is there a link between Parkinson’s disease and blood vessel dysfunction?
Scientists in Slovakia have investigated the link between blood vessel dysfunction and Parkinson’s – and found that dopamine agonists may have an impact. The team studied the function of the endothelium – a membrane which lines the heart and blood vessels and helps control blood fluidity – in 41 people with the condition and 41 people without. Endothelial function was then measured through a parameter that assessed how easily blood could flow through the vessels. The results showed that while more people with Parkinson’s had endothelial dysfunction compared to those without, the difference did not reach statistical significance. However, the researchers noted that the findings suggested “an association between smoking, dopamine agonists, and impaired endothelial function” in those with the condition. Outlining the study’s limitations, the team noted that more research is needed to explore this potential link.
New swab test may help with Parkinson’s disease diagnosis
Researchers at the University of Manchester, UK, have drawn on one woman’s sense of smell to develop a swab test that may be used to detect Parkinson’s. The scientists used the test to analyse sebum (a type of oily substance on the skin) in 79 people with Parkinson’s and a control group of 71 healthy individuals. The team identified more than 4,000 different compounds in the participant samples – including 500 that were unique to those living with the condition. The test was developed with the help of Joy Milne from Perth, Scotland, whose unique sense of smell meant that she noticed a change in her late husband Les’s odour twelve years before he was diagnosed with Parkinson’s. Speaking to the BBC, Professor Perdita Barran, who led the research, described the test as potentially “transformative” – and said that the team hopes to roll the test out to people in…
Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?
A biobank is a collection of biological samples and data designed to be used for research. Now, researchers in Australia are working to build a biobank for Parkinson’s. As part of the project, the scientists are conducting scans of people that have been injected with fluorodopa – a substance that highlights dopamine in the brain. Participants include people living with Parkinson’s and a control group of people without the condition. The resulting database of scans will be used to create a national biobank that aims to inform treatment and research into the condition. Commenting on the study, Olivia Nasser – executive director at the Hospital Research Foundation, which is helping to fund the research – said, “Once we build up the biobank of scans, it can actually be used as an effective way to treat Parkinson’s.” The researchers encourage people with and without Parkinson’s to take part in the trial.